Podcasts about Dyslipidemia

The World Cup is here, and while we watch some of the world's greatest athletes competing on a global stage, it's fascinating to consider what effect this intense activity may have on the human body. With that in mind, we're re-releasing our conversation with Stanford biochemist Jonathan Long on the future of exercise. Jonathan studies the chemistry of what happens inside your body when you move, and his findings are pointing toward some genuinely surprising possibilities — including treatments for obesity, diabetes, and even, someday, an exercise pill. If the athleticism on the pitch has you feeling inspired, this one is well worth another listen. Have a question for Russ? Send it our way in writing or via voice memo, and it might be featured on an upcoming episode. Please introduce yourself, let us know where you're listening from, and share your question. You can send questions to thefutureofeverything@stanford.edu. Episode Reference Links: Stanford Profile: Jonathan Long Connect With Us: Episode Transcripts >>> The Future of Everything Website Connect with Russ >>> Threads / Bluesky / Mastodon Connect with School of Engineering >>> Twitter/X / Instagram / LinkedIn / Facebook Chapters: (00:00:00) Introduction Russ Altman introduces guest Jonathan Long, a professor of pathology from Stanford University. (00:02:02) Effective Weight Loss Drugs The history and development of GLP-1 receptor agonists. (00:04:04) Understanding Metabolism and Exercise Why Long's lab starts with molecules to understand metabolism and physical activity. (00:05:10) Animal Models in Exercise Studies The use of animal models in exercise studies and the discovery of Lac-Phe. (00:06:47) Psychological Preparation for Exercise The psychological aspects of exercise and the involvement of endocannabinoids in exercise motivation. (00:09:00) Lac-Phe's Role and Mechanism The role of Lac-Phe and its production in the gut. (00:12:08) Differences in Exercise Response Differences in exercise response between trained athletes and untrained individuals. (00:12:57) Diabetes and Metabolic Diseases The relationship between diabetes, exercise, and metabolic diseases. (00:15:01) Lac-Phe as a Potential Therapeutic The potential of Lac-Phe as a weight loss drug, and parallels to GLP-1 drug development. (00:16:21) Importance of How Weight is Lost Whether the method of weight loss matters, and the importance of preserving lean muscle mass. (00:18:37) Exercise as Medicine The concept of exercise as medicine, and defining physical activity at the same resolution as modern medicines. (00:22:11) Metformin and Exercise Pathways The unexpected connection between metformin and the Lac-Phe pathway. (00:24:01) Prospects of an Exercise Pill The future of an exercise pill, and the challenges associated with its development. (00:27:05) Conclusion Final thoughts on the future of exercise. Connect With Us:Episode Transcripts >>> The Future of Everything WebsiteConnect with Russ >>> Threads / Bluesky / MastodonConnect with School of Engineering >>>Twitter/X / Instagram / LinkedIn / Facebook Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

The March 2026 ACC/AHA Guideline on the Management of Dyslipidemia made a major pivot regarding Lipoprotein(a) by establishing a formal recommendation for universal screening in adults. This 2026 guideline, published in the Journal of the American College of Cardiology, issued a Class 1 recommendation stating that every adult should have their Lp(a) measured at least once in their lifetime. Because Lp(a) levels are genetically determined and remain highly stable throughout a person's life, a single lifetime check is sufficient for the vast majority of the population to establish their baseline risk. Well, that's great for Family medicine or internal medicine, but how does that affect us in women's health? Well, it's complicated: lipoprotein(a) has been associated with an increased risk of VTE and has also been associated, in some studies, with FGR, preeclampsia, and preterm birth! So, can these patients receive oral contraceptives? What about Perioperative and postop care? Do these patients require anticoagulation? What about pregnancy- is LDA recommended here? And lastly, what about TXA use in patients with HMB? This podcast topic comes from one of our podcast family members who is an OBGYN military personnel caring for our wonderful troops overseas. Listen in for details!16% OFF TONA ACTIVE WEAR PROMO: https://tonaactive.com/discount/CHAPANOSPINOBG1. Ezzat, D., Lopez, D. M., Claggett, B. L., Li, L., Mohammadnia, N., Schuermans, A., Hemeryck, J., Chang, A., Murillo, S., O'Donoghue, M. L., Bikdeli, B., Yu, Z., Natarajan, P., Patel, A. P., Pabon, M. A., & Honigberg, M. C. (2026). Lipoprotein(a) and incident venous thromboembolism in pre- and postmenopausal women, and in men. European Heart Journal, ehag252. https://doi.org/10.1093/eurheartj/ehag2522.ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Dyslipidemia Writing Committee. (2026). 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia. Circulation, 153, e1155–e1300. https://doi.org/10.1161/CIR.00000000000014233. CDC MEC 4. Prevention of Venous Thromboembolism in Gynecologic Surgery: ACOG Practice Bulletin, Number 232. Obstetrics and Gynecology. 2021. Committee on Practice Bulletins—Gynecology5. Sofi F, Marcucci R, Abbate R, Gensini GF, Prisco D.Lipoprotein(a) as a Risk Factor for Venous Thromboembolism: A Systematic Review and Meta-Analysis of the Literature.Seminars in Thrombosis and Hemostasis. 2017. Dentali F, Gessi V, Marcucci R, et al. Lipoprotein (A) and Venous Thromboembolism in Adults: The American Journal of Medicine. 2007.

In this episode, we review key updates from the 2026 ACC-AHA Guidelines on the Management of Dyslipidemia. Key Concepts The PREVENT ASCVD equation is now recommended to calculate ASCVD risk, with thresholds at 3%, 5%, and 10%. The previous 7.5% threshold for statin treatment is now 5%. In addition to the 10-year ASCVD estimate, clinicians should consider the use of Lp(a), "risk enhancers", and coronary artery calcium (CAC) scans as a "tie breaker" with shared decision-making when the decision to treat is not clear. In addition to LDL goals of < 100, < 70, or < 55 (depending on risk), the new guidelines also suggest non-HDL-C and apoB goals once LDL cholesterol is at goal. Many patients will require non-statin therapies to achieve lipid goals. The recommended non-statin therapies include ezetimibe, PCSK9 mAb, PCSK9-interfering RNA, and bempedoic acid. References Writing Committee Members, Blumenthal RS, Morris PB, et al. 2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2026;153(17):e1154-e1276. doi:10.1161/CIR.0000000000001423 Wiggins BS, Barac A, Benziger CP, et al. 2026 Dyslipidemia Guideline-at-a-Glance. J Am Coll Cardiol. 2026;87(19):2617-2623. doi:10.1016/j.jacc.2026.02.4872 Superko H, Garrett B. Small Dense LDL: Scientific Background, Clinical Relevance, and Recent Evidence Still a Risk Even with 'Normal' LDL-C Levels. Biomedicines. 2022;10(4):829. Published 2022 Apr 1. doi:10.3390/biomedicines10040829

The provided source explores the physiological relationship between insulin resistance and dyslipidemia, focusing on how specific enzymes disrupt blood lipid levels. It explains that this condition arises from a functional imbalance between two key lipases responsible for processing fats. Specifically, a reduction in lipoprotein lipase activity prevents the body from clearing triglycerides, causing them to accumulate in the bloodstream. Simultaneously, an increase in hormone-sensitive lipase triggers the excessive release of stored fatty acids from fat cells into the plasma. Together, these enzymatic shifts produce the elevated fat concentrations typically observed in metabolic disorders. This overview highlights the underlying biochemical mechanisms that drive lipid imbalances in insulin-resistant individuals.

Updated cholesterol guidelines introduce important changes in cardiovascular risk assessment and lipid management that directly impact pharmacist practice. This course reviews key updates from the new ACC/AHA dyslipidemia guideline, including risk assessment tools, LDL-C targets, and evolving roles for statin and nonstatin therapies. You will be better prepared to identify practice-relevant recommendations and support evidence-based lipid management in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsJanelle Ruisinger, PharmD, FAPhAAssociate Dean for Academic Affairs and Clinical ProfessorThe University of Kansas School of PharmacyPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by enrolling in the course. Click here to enroll!CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe key pharmacist-relevant updates in the new ACC/AHA Guideline for the Management of Dyslipidemia.2. Differentiate risk assessment and lipid-lowering treatment considerations that may influence pharmacist recommendations under the updated guideline.Rachel Maynard and Janelle Ruisinger have no relevant financial relationships to disclose.0.75 CEU/0.75 HrUAN: 0107-0000-26-156-H01-PInitial release date: 5/4/2026Expiration date: 5/4/2027Additional CPE details can be found here.

Updated cholesterol guidelines introduce important changes in cardiovascular risk assessment and lipid management that directly impact pharmacist practice. This course reviews key updates from the new ACC/AHA dyslipidemia guideline, including risk assessment tools, LDL-C targets, and evolving roles for statin and nonstatin therapies. You will be better prepared to identify practice-relevant recommendations and support evidence-based lipid management in patient care.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsJanelle Ruisinger, PharmD, FAPhAAssociate Dean for Academic Affairs and Clinical ProfessorThe University of Kansas School of PharmacyGET CE FOR LISTENING!Stay Compliant. Grow Clinically. Practice with Confidence. Pharmacist CE Subscription: All your CE in one convenient subscription. All episodes, CE, and Practice Resources for the GameChangers Clinical Update is included with your Pharmacist CE Subscription. But wait…there's even more!The Pharmacist CE Subscription includes: -  Compliance and licensure CE -  GameChangers Clinical Updates -  Practical continuing education across patient care topics *The subscription does not include microcredentials or certificates, which are available separately for pharmacists seeking specialized service training. Purchase Now!PRACTICE RESOURCEReceive the exclusive Practice Resource to use as a reference guide for this episode by purchasing the Pharmacist CE Subscription. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation to claim credit:If you are already enrolled in this course, click here to redeem your credit. To purchase the Pharmacist CE Subscription and claim your CPE credit, click here or to purchase this course individually, click here.  CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe key pharmacist-relevant updates in the new ACC/AHA Guideline for the Management of Dyslipidemia.2. Differentiate risk assessment and lipid-lowering treatment considerations that may influence pharmacist recommendations under the updated guideline.Rachel Maynard and Janelle Ruisinger have no relevant financial relationships to disclose.0.75 CEU/0.75 HrUAN: 0107-0000-26-156-H01-PInitial release date: 5/4/2026Expiration date: 5/4/2027Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

This week, please join Chair Roger Blumenthal and author Gregg Fonarow as they discuss the recently published "2026 ACC/AHA/AACVPR/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Dyslipidemia" along with an accompanying commentary "The 2026 American College of Cardiology/American Heart Association Multisociety Guideline on the Management of Dyslipidemia: A More Precise—But More Complicated—Framework for Atherosclerotic Cardiovascular Disease Prevention and Treatment." For the episode transcript, visit: https://www.ahajournals.org/do/10.1161/podcast.20260427.104601

Roxana Mehran speaks with Ann Marie Navar about the latest advice on LDL cholesterol, Lp(a), coronary artery calcium, and more.

Commentary by Dr. Jian'an Wang.

In this minisode, Alex breaks down the 2026 ACC/AHA Dyslipidemia Guidelines, highlighting what's new and how it impacts both NP board exams and clinical practice. You'll learn the key updates, including a stronger emphasis on primary prevention, individualized care, and new diagnostic tools, while also being reassured that your current study plan is right on track.       Follow us on Instagram: instagram.com/smnpreviewsofficial

Listener feedback, the huge CLOSURE-AF trial of LAAC vs best medical therapy, previews of CHAMPION AF, and the controversial ACC/AHA lipid treatment guidelines are the topics John Mandrola, MD, discusses in this week's podcast. This podcast is intended for healthcare professionals only. To read a partial transcript or to comment, visit: https://www.medscape.com/twic I Listener Feedback COBRRA Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2510703 Closure AF published in NEJM CLOSURE-AF Trial https://www.nejm.org/doi/full/10.1056/NEJMoa2513310 CHAMPION AF Rationale - Watchman FLX vs DOACs in Patients With AF https://pubmed.ncbi.nlm.nih.gov/37279840/ LIPID Guidelines ACC/AHA Joint Committee Guideline on Management of Dyslipidemia https://www.jacc.org/doi/10.1016/j.jacc.2025.11.016 You may also like: The Bob Harrington Show with the Stephen and Suzanne Weiss Dean of Weill Cornell Medicine, Robert A. Harrington, MD. https://www.medscape.com/author/bob-harrington Questions or feedback, please contact news@medscape.net

Lipids remain central to cardiovascular prevention. The 2026 ACC/AHA Dyslipidemia Guideline introduces several important shifts:   • PREVENT equations replace older ASCVD risk calculators • Lipoprotein(a) measurement recommended at least once in all adults • ApoB helps identify residual lipoprotein risk • Coronary artery calcium scoring refines treatment decisions • LDL-C targets return, with

Join endocrine expert Dr. David Lieb as he moderates a discussion with Dr. Shailendra Patel, Chair of the 2025 AACE Dyslipidemia Algorithm; Dr. Maria Belalcazar, Vice Chair; and Dr. Robert Hegele, Author and Representative of the Canadian Cardiovascular Society, about the 2025 Updated Algorithm for Management of Adults with Dyslipidemia.This episode covers:The rationale behind updating the algorithm and how it aligns with the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with DyslipidemiaKey updates from the 2020 algorithm, including expanded guidance on hypertriglyceridemia and lipid management in special populationsPractical strategies for integrating the algorithm into everyday clinical practice and medical education with an emphasis on patient-centered care, shared decision making, and health equityEmerging therapies on the horizon and priority areas for future research Tune in to hear expert insights on how this updated, evidence-based resource can support better clinical decision making and improve patient outcomes.

We are discussing perspective changes in neurology genetics with the crossover of the APOE gene in neuro and cardio as well as telehealth for neurology predictive testing. Segment 1: Is it time for a paradigm shift? Inclusion of APOE  on genetic dyslipidemia panels.   Emily Brown is a certified genetic counselor at the Center for Inherited Heart Disease at Johns Hopkins Hospital. She graduated from the University of Maryland Genetic Counseling Program in 2014 and has practiced in cardiology for the past 10 years. Her main areas of interest include dyslipidemias, and she is a member of the National Lipid Association.   Hannah Ison is a cardiovascular genetic counselor at the Stanford Center for Inherited Cardiovascular Disease. She received her Master's in Medical and Molecular Genetics from Indiana University in 2018, and returned home to California to begin her career. Her primary clinical interest includes working with patients who have inherited lipid conditions in both the adult and pediatric setting. A large part of her role has been focused on developing a Pediatric Lipid Clinic at the Stanford Children's Hospital, allowing her to care for patients across the generations. Hannah was the co-chair of the Dyslipidemia Working Group through the cardiovascular SIG from 2020-2024 where she worked with members to develop dyslipidemia resources. In addition to her work in the lipid space, she also provides inpatient and outpatient genetic counseling to patients with isolated congenital heart disease, and enjoys participating in various research opportunities.    In this segment we discuss: - APOE's relevance in both Alzheimer's and cardiovascular disease - Counseling strategies for APOE alleles (ε2, ε3, and ε4), including penetrance, lifestyle modification, and exploration of risk for conditions and symptoms external to Alzheimer's - Case studies highlighting APOE's diagnostic, variant, and treatment insights - The need for standardization, education, and reframing of APOE testing in practice Segment 2: Patient-reported outcomes for remote and in-person visits for genetic counseling in adult neurology.   Rachel A. Paul, MS, CGC and Laynie Dratch, ScM, CGC are board-certified genetic counselors who specialize in adult neurogenetics and work with the Penn Neurogenetics Therapy Center team in Philadelphia, PA (https://www.linkedin.com/company/penn-neurogenetics-therapy-center).   Rachel provides clinical and research genetic counseling services for the Division of Movement Disorders at the University of Pennsylvania. Her research interests include genetic screening for clinical trials access, remote/telemedicine genetic services, and motivations/barriers for genetics utilization. She graduated cum laude from Temple University in Philadelphia, previously worked as a genetic counseling assistant (GCA) for the Penn neurogenetics program, and completed her training with the Arcadia University (now University of Pennsylvania) Genetic Counseling Program.   Laynie's clinical focus includes frontotemporal degeneration (FTD) spectrum disorders, amyotrophic lateral sclerosis (ALS), and other neurodegenerative conditions. Her research interests include the lived experiences of at-risk individuals, predictive genetic testing considerations, and genetic counseling access and service delivery. She graduated summa cum laude from Colgate University with a BA in neuroscience and a minor in psychology, and completed her genetic counseling masters training at the Johns Hopkins University and the National Institutes of Health.   In this segment we discuss: - How COVID-19 pushed neurogenetics counseling from in-person to telehealth. - Why patient satisfaction stayed high across both formats, with video outperforming phone. - What drives visit preferences—travel, tech comfort, privacy, and clinical needs. - Future research to refine protocols, improve access, and explore broader applications.   Would you like to nominate a JoGC article to be featured in the show? If so, please fill out this nomination submission form here. Multiple entries are encouraged including articles where you, your colleagues, or your friends are authors.   Stay tuned for the next new episode of DNA Dialogues! In the meantime, listen to all our episodes Apple Podcasts, Spotify, streaming on the website, or any other podcast player by searching, “DNA Dialogues”.    For more information about this episode visit dnadialogues.podbean.com, where you can also stream all episodes of the show. Check out the Journal of Genetic Counseling here for articles featured in this episode and others.    Any questions, episode ideas, guest pitches, or comments can be sent into DNADialoguesPodcast@gmail.com.    DNA Dialogues' team includes Jehannine Austin, Naomi Wagner, Khalida Liaquat, Kate Wilson and DNA Today's Kira Dineen. Our logo was designed by Ashlyn Enokian. Our current intern is Stephanie Schofield.

Welcome to HCPLive's 5 Stories in Under 5—your quick, must-know recap of the top 5 healthcare stories from the past week, all in under 5 minutes. Stay informed, stay ahead, and let's dive into the latest updates impacting clinicians and healthcare providers like you! Interested in a more traditional, text rundown? Check out the HCPFive! Top 5 Healthcare Headlines for August 17-23, 2025: 1. FDA Approves Donidalorsen to Prevent Hereditary Angioedema Attacks The FDA approved donidalorsen (DAWNZERA) for preventing HAE attacks in patients 12 years and older, supported by phase 3 OASIS trial data. 2. FDA Grants Atumelnant Orphan Drug Designation for Congenital Adrenal Hyperplasia Atumelnant received FDA Orphan Drug Designation after phase 2 results showed rapid, sustained reductions in key biomarkers for congenital adrenal hyperplasia. 3. Semaglutide Reduces Medical Costs, Healthcare Resource Utilization in Heart Failure A real-world analysis found semaglutide 2.4 mg reduced all-cause medical costs by 28% and inpatient hospitalization costs by 55% in patients with obesity and heart failure. 4. RE104 Reduces Postpartum Depression Symptoms by Day 7 in Phase 2 RECONNECT RE104 significantly reduced depressive symptoms by day 7 in patients with postpartum depression, meeting the phase 2 RECONNECT trial's primary endpoint. 5. Dyslipidemia, Other Metabolic Syndrome Factors May Raise Parkinson's Disease Risk People with metabolic syndrome had about a 40% higher risk of developing Parkinson's disease compared with those without the condition.

Olive Peloponnese, a 50 year old woman with coming in to review her “bad cholesterol.”

This activity was supported by an educational grant from Merck & Co., Inc. Please go to ⁠⁠⁠⁠⁠https://academiccme.com/front-matter/esc25-1/⁠ and complete the evaluation to receive your CE/CME Credit. Credit is available through August 20, 2026.

Dyslipidemia remains a major contributor to cardiovascular disease, and pharmacists play a key role in optimizing therapy and improving outcomes. This episode reviews recent updates in guidelines, pharmacologic options, and practical counseling tips for supporting patients with lipid disorders. Tune in to strengthen your clinical impact and support long-term health for the patients you serve. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJanelle Ruisinger, PharmD, FAPhAClinical ProfessorThe University of Kansas School of PharmacyPharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current guidelines and evidence-based pharmacologic options for managing dyslipidemia.2. Identify key counseling strategies pharmacists can use to support adherence and improve lipid-related outcomes.0.05 CEU/0.5 HrUAN: 0107-0000-25-226-H01-PInitial release date: 6/30/2025Expiration date: 6/30/2026Additional CPE details can be found here.

Dyslipidemia remains a major contributor to cardiovascular disease, and pharmacists play a key role in optimizing therapy and improving outcomes. This episode reviews recent updates in guidelines, pharmacologic options, and practical counseling tips for supporting patients with lipid disorders. Tune in to strengthen your clinical impact and support long-term health for the patients you serve. HOSTJoshua Davis Kinsey, PharmDVP, EducationCEimpactGUESTJanelle Ruisinger, PharmD, FAPhAClinical ProfessorThe University of Kansas School of PharmacyPharmacist Members, REDEEM YOUR CPE HERE! Not a member? Get a Pharmacist Membership & earn CE for GameChangers Podcast episodes! (30 mins/episode)CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe current guidelines and evidence-based pharmacologic options for managing dyslipidemia.2. Identify key counseling strategies pharmacists can use to support adherence and improve lipid-related outcomes. 0.05 CEU/0.5 HrUAN: 0107-0000-25-226-H01-PInitial release date: 6/30/2025Expiration date: 6/30/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Acesse o Guia de bolso de IOT do TdC no link: http://bit.ly/4dyi6n8Pedro Magno e Lucca Cirillo conversam sobre os alvos de LDL em 4 populações:- Evento cardiovascular prévio- Presença de diabetes- LDL > 190 mg/dL- Outras situações Veja mais em https://www.tadeclinicagem.com.br/guia/259/hipercolesterolemia-familiar/Veja o vale a pena ouvir de novo em https://www.youtube.com/watch?v=k42rmssU1xE&ab_channel=TadeClinicagemReferências:1. Mach, François et al. “2019 ESC/EAS Guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk.” European heart journal vol. 41,1 (2020): 111-188. doi:10.1093/eurheartj/ehz4552. Faludi, André Arpad et al. “Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017.” Arquivos brasileiros de cardiologia vol. 109,2 Supl 1 (2017): 1-76. doi:10.5935/abc.201701213. Grundy, Scott M et al. “2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA Guideline on the Management of Blood Cholesterol: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.” Journal of the American College of Cardiology vol. 73,24 (2019): 3168-3209. doi:10.1016/j.jacc.2018.11.0024. Pearson, Glen J et al. “2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia for the Prevention of Cardiovascular Disease in Adults.” The Canadian journal of cardiology vol. 37,8 (2021): 1129-1150. doi:10.1016/j.cjca.2021.03.0165. Marx, Nikolaus et al. “2023 ESC Guidelines for the management of cardiovascular disease in patients with diabetes.” European heart journal vol. 44,39 (2023): 4043-4140. doi:10.1093/eurheartj/ehad1926. Vrints, Christiaan et al. “2024 ESC Guidelines for the management of chronic coronary syndromes.” European heart journal vol. 45,36 (2024): 3415-3537. doi:10.1093/eurheartj/ehae1777. Hong, Sung-Jin et al. “Treat-to-Target or High-Intensity Statin in Patients With Coronary Artery Disease: A Randomized Clinical Trial.” JAMA vol. 329,13 (2023): 1078-1087. doi:10.1001/jama.2023.24878. Cannon, Christopher P et al. “Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes.” The New England journal of medicine vol. 372,25 (2015): 2387-97. doi:10.1056/NEJMoa14104899. Sabatine, Marc S et al. “Evolocumab and Clinical Outcomes in Patients with Cardiovascular Disease.” The New England journal of medicine vol. 376,18 (2017): 1713-1722. doi:10.1056/NEJMoa161566410. http://departamentos.cardiol.br/sbc-da/2015/calculadoraer2017/etapa1.html11. Lipidology update: targets and timing of well-established therapies, Luigina Guasti 1, MD, PhD, FAHA, FESC; Alessandro Lupi 2, MD at https://www.escardio.org/Councils/Council-for-Cardiology-Practice-(CCP)/Cardiopractice/lipidology-update-targets-and-timing-of-well-established-therapies12. Ray, Kausik K et al. “EU-Wide Cross-Sectional Observational Study of Lipid-Modifying Therapy Use in Secondary and Primary Care: the DA VINCI study.” European journal of preventive cardiology vol. 28,11 (2021): 1279-1289. doi:10.1093/eurjpc/zwaa04713. Cholesterol Treatment Trialists' (CTT) Collaboration et al. “Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.” Lancet (London, England) vol. 376,9753 (2010): 1670-81. doi:10.1016/S0140-6736(10)61350-5

On this episode we review the 2025 Clinical Practice Guideline for the Pharmacologic Management of Adults with Dyslipidemia published by the American Association of Clinical Endocrinology. We compare and contrast the common medications used in the management of dyslipidemia and examine how these can be utilized based on the 13 updated recommendations found in the 2025 guidelines.  Cole and I are happy to share that our listeners can claim ACPE-accredited continuing education for listening to this podcast episode! We have continued to partner with freeCE.com to provide listeners with the opportunity to claim 1-hour of continuing education credit for select episodes. For existing Unlimited (Gold) freeCE members, this CE option is included in your membership benefits at no additional cost! A password, which will be given at some point during this episode, is required to access the post-activity test. To earn credit for this episode, visit the following link below to go to freeCE's website: https://www.freece.com/ If you're not currently a freeCE member, we definitely suggest you explore all the benefits of their Unlimited Membership on their website and earn CE for listening to this podcast. Thanks for listening! If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. If you purchase an annual membership, you'll also get a free digital copy of High-Powered Medicine 3rd edition by Dr. Alex Poppen, PharmD. HPM is a book/website database of summaries for over 150 landmark clinical trials.You can visit our Patreon page at the website below:  www.patreon.com/corconsultrx We want to give a big thanks to Dr. Alex Poppen, PharmD and High-Powered Medicine for sponsoring the podcast..  You can get a copy of HPM at the links below:  Purchase a subscription or PDF copy - https://highpoweredmedicine.com/ Purchase the paperback and hardcover - Barnes and Noble website We want to say thank you to our sponsor, Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx We also want to thank our sponsor Freed AI. Freed is an AI scribe that listens, prepares your SOAP notes, and writes patient instructions. Charting is done before your patient walks out of the room. You can try 10 notes for free and after that it only costs $99/month. Visit the website below for more information: https://www.getfreed.ai/  If you have any questions for Cole or me, reach out to us via e-mail: Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com

This interview with JACC: Associate Editor Neha J. Pagidipati, MD, FACC, and author Kausik Ray, MD, FACC, reviews Dr. Ray's phase one study on solbinsiran, an siRNA therapy targeting ANGPTL3 to reduce triglycerides and cardiovascular risk. Dr. Ray explains the study's findings, including significant reductions in triglycerides, ApoB, and LDL, with a favorable safety profile. The conversation also touches on the broader landscape of ANGPTL3 inhibitors, the implications of HDL reduction, and the anticipation of phase two results to be presented at ACC 2025.

In today's episode, we are happy to hear from our clinic's Dr. Scott and one of his patients, Keith about his successful experience tackling gut health issues. Keith's case posed a very common conundrum that we've seen in many with gut health issues - are we dealing with bacterial overgrowth (SIBO), fungal overgrowth (candida) or potentially both? We'll walk through some of the key indications that Keith's initial SIBO diagnosis was actually a candida case, and we'll cover the best testing and treatments that led to Keith's recovery.  Need help navigating your digestive or other health conditions? Learn more about our virtual clinic: https://drruscio.com/virtual-clinic/

New RNA Therapies for Treatment of ASCVD, Prevention, and Dyslipidemia   Guest: R. Scott Wright, M.D. Host: Stephen L. Kopecky, M.D.   RNA therapies are growing in number as targeted treatments for dyslipidemia including LDL-c, Lp(a) and Triglycerides. The podcast will explore the science behind these therapies, the evidence for safety and how clinicians can utilize them in their practices.    Topics Discussed: What are the new RNA therapies available or soon to be available? How are RNA based therapies being used? How do they compare to the COVID-19 vaccine? What is their effectiveness and side effect profile? Are there side effects or concerns?   Connect with Mayo Clinic's Cardiovascular Continuing Medical Education online at https://cveducation.mayo.edu or on Twitter @MayoClinicCV and @MayoCVservices. LinkedIn: Mayo Clinic Cardiovascular Services Cardiovascular Education App: The Mayo Clinic Cardiovascular CME App is an innovative educational platform that features cardiology-focused continuing medical education wherever and whenever you need it. Use this app to access other free content and browse upcoming courses. Download it for free in Apple or Google stores today! No CME credit offered for this episode. Podcast episode transcript found here.

Welcome back Rounds Table Listeners!We are back this week with a special podcast episode! Dr. Mike Fralick sits down with Dr. Amy Yu, a Stroke Neurologist, Clinician-Scientist, and Associate Professor of Medicine at the University of Toronto and Sunnybrook Hospital, to chat about her hot-off-the press publication - Population-Level Screening for Diabetes and Dyslipidemia After Pregnancies Complicated by Hypertension or Diabetes!Questions? Comments? Feedback? We'd love to hear from you! @roundstable @InternAtWork @MedicinePods

LATE BREAKING CLINICAL SCIENCE: Benefits of Dynamx Bioadaptor Versus DES in Patients With Dyslipidemia: Subgroup Analysis Results from the BIOADAPTOR RCT

Join Dr. David Lieb as he moderates an engaging discussion with Dr. Shailendra Patel, Chair of the Dyslipidemia Guideline Task Force, and Dr. Kathleen Wyne, Vice Chair, about the recently released 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.This episode covers:What's new or different in this update compared to the 2017 guideline.Surprising insights revealed during the evidence assessments and how they shaped the recommendations.Key considerations for clinicians as they integrate these updated recommendations into practice.Gaps in the literature and opportunities for future research.Whether you're familiar with the previous guideline or new to this topic, this conversation provides a comprehensive overview of the latest advancements in dyslipidemia management.

In this episode, join moderator Dr. David Lieb alongside esteemed panelists Dr. Shahnaz Sultan, Dr. Carol Peng, and Dr. Melanie Bird as they delve into the methodology behind the 2025 AACE Clinical Practice Guideline on Pharmacologic Management of Adults with Dyslipidemia.Discover insights into:Why AACE adopted the GRADE framework and its implications for guideline development.The critical role of systematic reviews in creating evidence-based recommendations.How evidence is assessed using the GRADE approach.Practical takeaways for clinicians when implementing GRADE-informed guidelines in patient care.Whether you're a seasoned practitioner or new to the field, this discussion offers valuable perspectives on the evolution of evidence-based guideline development and its impact on clinical practice.

DCS 1403: DLP

This episode delves into the intricate relationship between diabetes and dyslipidemia, exploring how insulin resistance affects liver function, leading to an imbalance in cholesterol levels. Abnormal cholesterol levels often accompany abnormal A1c levels. Historically, statin therapy has been a cornerstone in dyslipidemia treatment, recent research challenges its effectiveness, tying statin use to worsening insulin resistance and hormonal balance. I point out the importance of dietary interventions, emphasizing the detrimental effects of processed foods on health. In the end, I encourage you to embark on a 90-day journey of eliminating processed foods to reclaim your health. Check it out! Tell me how it goes!

On this episode of Ancestral Health Today we bring you Naturopathic doctor, coach and Author Nadia Pateguana, N.D - Dr, Pateguana works with clients from a holistic perspective, not seeing organs or illnesses, but seeing people. She is a graduate from The Canadian College of Naturopathic Medicine (www.ccnm.edu) in 2004 and has a Degree in Honours Biology from McMaster University (2000).  Dr. Pateguana's interest has always been how to heal the human body. In search for her own wellness, she discovered Naturopathic Medicine.She believes in the Healing Power of Nature; the body's ability to heal itself. The first and foremost Principle is "To Do No Harm", and she tries to follow this to the best of her capacity at all times. With a strong science-based approach, CCNM's 4 year program includes TCM (Traditional Chinese Medicine) and Acupuncture, Homeopathy, Nutrition, Counselling, and all the other Medical Sciences. Her focus has always been on Nutrition. Mostly, she uses FOOD as medicine!She was born in Mozambique, but raised in Canada, where she completed her studies, and then, life took her back to her home country for ten years. There, she ran a multidisciplinary clinic as the Medical Director and Naturopathic Doctor. Currently, and proudly, she swork as a Health Consultant with Dr. Jason Fung and Megan Ramos at the The Fasting Method by IDM since 2016. The TFM program recommends a Real Food and Intermittent Fasting approach to help people overcome Insulin Resistance and Metabolic Syndrome conditions such as Obesity, Diabetes, Fatty Liver, PCOS, Hypertension, Dyslipidemia, Inflammation, Pain and the like. Her special focus is on helping women with PCOS overcome infertility through dietary modifications.In April of 2020, her first book written with the best-selling author Dr. Jason Fung, titled "The PCOS Plan: Prevent and Reverse Polycystic Ovary Syndrome through Diet and Fasting" was published and released. Check out her site for advice on Insulin Resistance, Women's Health, Fasting, Diet and practical recipes.Enjoy this conversation with Dr. Pateguana.  Get full access to Ancestral Health Today Substack at ancestralhealth.substack.com/subscribe

This podcast will discuss Approach to Childhood Dyslipidemia. The podcast was created by Katherine Tom, a final year medical student at McMaster University in Hamilton. This podcast was created under the supervision of clinical practice update author, Dr. Peter Wong, a community pediatric cardiologist and Associate Professor in the Department of Pediatrics at the University of Toronto. This PedsCases podcast aims to provide an approach to childhood dyslipidemia, reviewing components of the CPS statement: “The Detection, Evaluation, and Management of Dyslipidemia in Children and Adolescents.”

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

In this episode, Arun B. Jesudian, MD, and Mazen Noureddin, MD, MHSc, discuss the expert-informed clinical pathway for the multidisciplinary care of patients with MASLD or MASH, current and emerging therapeutics, and management optimization strategies. Presenters:Arun B. Jesudian, MDAssociate Professor of Clinical MedicineDivision of Gastroenterology and HepatologyWeill Cornell MedicineNew York, New YorkMazen Noureddin, MD, MHScProfessor of MedicineHouston Methodist HospitalDirector Houston Research InstituteHouston, TexasContent based on an online CME program supported by independent educational grants from Novo Nordisk.To view the full program on “Clinical Pathways: Multidisciplinary Approach to Managing Metabolic Dysfunction‒Associated Steatohepatitis,” including 4 CME/CE-certified text modules with accompanying slidesets, 4 ClincalThought commentaries, and a downloadable infographic resource on the AGA MASLD MASH Clinical Care Pathway, visit clinicaloptions.com or click on the link below.Link to full program:https://bit.ly/3Tyu7At

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo Clinic Deepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo ClinicDeepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

Dyslipidemia is a well-known risk factor for the development of cardiovascular disease, a leading cause of morbidity and mortality. Treatment of dyslipidemia represents one of the most crucial strategies to reduce risk of atherosclerotic cardiovascular (CV) disease (ASCVD). In this podcast series, Dr. Deepak Bhatt and Dr. R. Scott Wright discuss recent clinical trial evidence for CV risk reduction with cholesterol-lowering therapies, with a focus on CV outcomes trials with current and emerging therapies that target proprotein convertase subtilisin/kexin type 9 (PCSK9).Launch Date: February 16, 2024Release Date: January 29, 2024Expiration Date: January 31, 2025FACULTYR. Scott Wright, MD, FACC, FESC, FAHAProfessor of MedicineConsultant in CardiologyMayo ClinicDeepak L. Bhatt, MD, MPH, FACC, FAHA, FESC, MSCAIDirectorMount Sinai Fuster Heart HospitalDr. Valentin Fuster Professor of Cardiovascular MedicineIcahn School of Medicine at Mount SinaiThis podcast provides accredited continuing education credits. To qualify for credit, please read all accreditation information at the provided link below prior to listening to this episode.https://www.practicepointcme.com/CMEHome/talking-cardiovascular-disease-prevention-emerging-strategies-to-address-management-challenges-in-dyslipidemia-1

We all know that a sedentary lifestyle is not healthy for anyone, but just how strongly is physical activity connected to lipid levels in childhood? Host Aaron Lohr talks with Andrew Agbaje, MD, PhD, a physician and pediatric clinical epidemiologist at the University of Eastern Finland. He has authored a study recently published in The Journal of Clinical Endocrinology & Metabolism titled, “Associations of Sedentary Time and Physical Activity From Childhood With Lipids: A 13-Year Mediation and Temporal Study.” Show notes are available at https://www.endocrine.org/podcast/enp83-sedentary-time-and-physical-activity-effects-on-childhood-lipid-levels — for helpful links or to hear more podcast episodes, visit https://www.endocrine.org/podcast

You might have heard the buzz around berberine, often referred to as “nature's Ozempic”.   Berberine is a powerhouse for many things, from reducing inflammation to regulating blood sugar levels. Tune in to hear which benefits the science supports (and the surprising ones it doesn't) and get a simple dosing guide.  And if you have any additional questions you would like answered in the future, let me know in the comments!   Watch/Read Next… Diets Debunked: The Noom Program: https://drruscio.com/noom-debunked/  Diets Debunked: Weight Watchers: https://drruscio.com/weight-watchers/  Genetic Testing for Weight Loss Isn't Worth it. Here's what is: https://drruscio.com/genetic-testing-for-weight-loss/  How to Heal Your Gut Naturally: https://drruscio.com/how-to-heal-your-gut-naturally/     Timestamps 00:00 Intro  01:00 What is berberine?  01:37 Weight loss 02:34 Cholesterol 05:52 Blood sugar  08:47 Gut health  11:15 SIBO  12:53 Berberine dosing guide    Featured Studies  Biological properties and clinical applications of berberine: https://pubmed.ncbi.nlm.nih.gov/32335802/ Berberine: Botanical Occurrence, Traditional Uses, Extraction Methods, and Relevance in Cardiovascular, Metabolic, Hepatic, and Renal Disorders: https://pubmed.ncbi.nlm.nih.gov/30186157/  The Effect of Berberine on Reproduction and Metabolism in Women with Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomized Control Trials: https://pubmed.ncbi.nlm.nih.gov/31915452/ The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials: https://pubmed.ncbi.nlm.nih.gov/32690176/ The effect of berberine supplementation on lipid profile and obesity indices: An umbrella review of meta-analysis: https://www.sciencedirect.com/science/article/abs/pii/S2213434423000361  Berberine decreases plasma triglyceride levels and upregulates hepatic TRIB1 in LDLR wild type mice and in LDLR deficient mice: https://pubmed.ncbi.nlm.nih.gov/31666640/  Berberine decreases cholesterol levels in rats through multiple mechanisms, including inhibition of cholesterol absorption: https://pubmed.ncbi.nlm.nih.gov/25002181/ Overall and Sex-Specific Effect of Berberine for the Treatment of Dyslipidemia in Adults: A Systematic Review and Meta-Analysis of Randomized Placebo-Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/36941490/ Efficacy and Safety of Berberine Alone or Combined with Statins for the Treatment of Hyperlipidemia: A Systematic Review and Meta-Analysis of Randomized Controlled Clinical Trials: https://pubmed.ncbi.nlm.nih.gov/31094214/ The Effect of Berberine on Metabolic Profiles in Type 2 Diabetic Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/34956436/ Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials: https://pubmed.ncbi.nlm.nih.gov/37598753/ Effects of berberine and barberry on selected inflammatory biomarkers in adults: A systematic review and dose-response meta-analysis of randomized clinical trials: https://pubmed.ncbi.nlm.nih.gov/37675930/ Berberine improves intestinal epithelial tight junctions by upregulating A20 expression in IBS-D mice: https://pubmed.ncbi.nlm.nih.gov/31306972/ Berberine Enhances Intestinal Mucosal Barrier Function by Promoting Vitamin D Receptor Activity: https://pubmed.ncbi.nlm.nih.gov/37046128/ Berberine influences multiple diseases by modifying gut microbiota: https://pubmed.ncbi.nlm.nih.gov/37599699/ Berberine Improves Intestinal Motility and Visceral Pain in the Mouse Models Mimicking Diarrhea-Predominant Irritable Bowel Syndrome (IBS-D) Symptoms in an Opioid-Receptor Dependent Manner: https://pubmed.ncbi.nlm.nih.gov/26700862/ A Randomized Clinical Trial of Berberine Hydrochloride in Patients with Diarrhea-Predominant Irritable Bowel Syndrome: https://pubmed.ncbi.nlm.nih.gov/26400188/ Efficacy and safety of berberine in preventing recurrence of colorectal adenomas: A systematic review and meta-analysis: https://pubmed.ncbi.nlm.nih.gov/34509605/ Berberine and rifaximin effects on small intestinal bacterial overgrowth: Study protocol for an investigator-initiated, double-arm, open-label, randomized clinical trial (BRIEF-SIBO study): https://pubmed.ncbi.nlm.nih.gov/36873985/ Berberine and health outcomes: An umbrella review: https://pubmed.ncbi.nlm.nih.gov/36999891/ Bioavailability study of berberine and the enhancing effects of TPGS on intestinal absorption in rats: https://pubmed.ncbi.nlm.nih.gov/21637946/  Efficacy of berberine in patients with type 2 diabetes mellitus: https://pubmed.ncbi.nlm.nih.gov/18442638/    Get the Latest Updates Facebook - https://www.facebook.com/DrRusciodc Instagram - https://www.instagram.com/drrusciodc/ Pinterest - https://www.pinterest.com/drmichaelrusciodc    DISCLAIMER: The information on this site is not intended or implied to be a substitute for professional medical advice, diagnosis or treatment. Always seek the advice of your physician or other qualified healthcare provider before starting any new treatment or discontinuing an existing treatment. Music featured in this video: "Modern Technology" by Andrew G, https://audiojungle.net/user/andrew_g  *Full transcript available on YouTube by clicking the “Show transcript” button on the bottom right of the video.

Credits: 0.50 AMA PRA Category 1 Credits™, 0.50 ABIM MOC or 0.67 AANP, including 0.67 AANP Pharm   CME/CE Information and Claim Credit: https://www.pri-med.com/online-cme-ce/Podcast/cholesterol-chronicles    Overview: Through a case study approach, explore recommended treatments, dissect the components of the lipid panel, and engage in discussions on managing musculoskeletal side effects for patients on statins. Enhance your understanding of cholesterol management in this insightful exploration of the dyslipidemia maze.    Guest: Danielle Hebert, DNP, MBA, ANP-BC

In this final episode, the experts consider the patient perspective of managing type 2 diabetes and its complications while tailoring treatment approaches to individual characteristics. They also consider the patient's needs with a focus towards incretin/gut hormones and providing practical insights for healthcare practice.   This podcast is provided by EMJ and was supported by independent funding from Eli Lilly and Company, who did not influence the content of it. This educational activity is intended for an audience of non-US healthcare professionals.   Prof Michael Nauck Head of Clinical Research at the Diabetes Division Medical Department of St. Josef-Hospital, Ruhr-University in Bochum, Germany. Professor Nauck's research interests include the pivotal role of gastrointestinal peptide hormones, including incretins, in both the physiological and therapeutic regulation of metabolism, as well as in the pathophysiology of type 2 diabetes. His groundbreaking contributions have been significant in shaping the treatment landscape of type 2 diabetes. He has played a pivotal role in developing novel therapeutic agents based on anti-diabetic properties of the gut hormone including GLP-1 (or Glucagon-like peptide-1). His extensive scholarly output is underscored by numerous publications, and his outstanding scientific contributions have been honoured with several awards and accolades, including the Paul Langerhans Medal (2012) bestowed by the German Diabetes Association, and the Claude Bernard Medal from the European Association for the Study of Diabetes in 2022.   Dr. Priya Manjoo Clinical Assistant Professor in the Division of Endocrinology at the University of British Columbia in Canada.  Dr Manjoo is a diplomat of the American Board of Obesity Medicine and a Certified Specialist in Hypertension Medicine. She is also the director of the CardioMetabolic Collaborative Clinic located in Victoria, British Columbia, Canada and a member of the Victoria Lipid Clinic. She is a co-author of the Pharmacotherapy Section of the 2020 Canadian Adult Obesity Clinical Practice guidelines, as well as the 2022 chapter update and is an author of the 2021 Canadian Cardiovascular Society Guidelines for the Management of Dyslipidemia in Adults. Dr. Manjoo is a key opinion leader in the realms of diabetes, dyslipidaemia, and obesity management. Her invaluable contributions significantly contribute to advancing our understanding of these critical medical concepts.

Alan Brown, MD, FNLA talks with Carol F. Kirkpatrick, PhD, MPH, RDN, CLS, FNLA and Kevin C Maki, PhD, CLS, FNLA, FTOS, FACN to discuss Nutrition Interventions for Adults with Dyslipidemia. 

A 65-year-old woman has hypertension, dyslipidemia, type 2 diabetes, a 50 pack-year history of cigarette smoking, currently smoking ½ PPD,  and stage 3B chronic kidney disease (CKD)  (GFR = 37 mL/min/1.73 m2). She is not currently taking any dyslipidemia therapy and her LDL= 140 mg/dL. Which of the following represents the most appropriate pharmacologic intervention for treatment of dyslipidemia?A. Owing to her age and comorbidity, no further intervention is required.B. Moderate-intensity statin therapy is the preferred treatment option.C. Niacin should be prescribed.D. The use of ezetimibe (Zetia®) will likely be sufficient to achieve dyslipidemia control.---YouTube: https://www.youtube.com/watch?v=up_iIweB9Ic&list=PLf0PFEPBXfq592b5zCthlxSNIEM-H-EtD&index=27Visit fhea.com to learn more!

Commentary by Dr. Valentin Fuster

This week on Pharm5: Mifepristone's FDA approval up in the air Statins for primary prevention in PLWH Xylazine sedative found in illicit fentanyl Death by H3N8 avian flu Phase II Match Day In in honor of National Minority Health Month, this week's episode was fully written, developed, and recorded by members of the Student National Pharmaceutical Association (SNPhA) at the HSC College of Pharmacy. Thank you to SNPhA members Hillary Matthews, Alyssa Ching, Jalyn Vance, Brizeek Martin, Lauren Robertson, ChiChi Opara, Jared Mitchell, Jasmine Hill, and Alexis Zamora for your contributions!                                                                                           Connect with us! Listen to our podcast: Pharm5 Follow us on Twitter: @LizHearnPharmD References: Perrone M, Weber PJ. Access to abortion pill in limbo after competing rulings. AP NEWS. http://bit.ly/3KDc9qU. Published April 8, 2023. Accessed April 13, 2023. Bose N. White House plans support for drugstores, pharma in Abortion Pill Battle. Reuters. http://bit.ly/3o9pekg. Published April 10, 2023. Accessed April 13, 2023.  Stein P, Marimow AE, Masih N. Appeals Court temporarily keeps abortion pill available but limits access. The Washington Post. http://bit.ly/41mQIRO. Published April 13, 2023. Accessed April 13, 2023.  Daily statin reduces the risk of cardiovascular disease in people living with HIV, large NIH study finds. National Institutes of Health. http://bit.ly/41rv7aR. Published April 11, 2023. Accessed April 13, 2023. Triant VA. Cardiovascular disease and HIV infection. Curr HIV/AIDS Rep. 2013;10(3):199-206. doi:10.1007/s11904-013-0168-6 Nakagomi A, Shibui T, Kohashi K, et al. Differential Effects of Atorvastatin and Pitavastatin on Inflammation, Insulin Resistance, and the Carotid Intima-Media Thickness in Patients with Dyslipidemia. J Atheroscler Thromb. 2015;22(11):1158-1171. doi:10.5551/jat.29520 Hoffman J. White House designates animal sedative as an 'emerging drug threat'. The New York Times. http://bit.ly/3o07pE7. Published April 12, 2023. Accessed April 13, 2023.  Biden-Harris Administration designates fentanyl combined with xylazine as an emerging threat to the United States. The White House. http://bit.ly/3GFiIbr. Published April 12, 2023. Accessed April 13, 2023.  China reports first human death from H3N8 bird flu: Who – DW – 04/12/2023. dw.com. http://bit.ly/3o1LWuw. Published April 12, 2023. Accessed April 13, 2023. Baz M, Paskel M, Matsuoka Y, et al. A single dose of an avian H3N8 influenza virus vaccine is highly immunogenic and efficacious against a recently emerged seal influenza virus in mice and ferrets. Journal of Virology. 2015;89(13):6907-6917. doi:10.1128/jvi.00280-15 China Records World's first human death from H3N8 bird flu, WHO says. Reuters. https://bit.ly/3KxAJcR. Published April 12, 2023. Accessed April 13, 2023. American Society of Health-System Pharmacists resident matching program. https://bit.ly/3UDaTsG.  Accessed April 13, 2023. ASHP match statistics. ASHP Match | Statistics of the Match. https://bit.ly/42e4Ga1. Published March 15, 2023. Accessed April 13, 2023. Overview of the match. ASHP Match | Overview of the Match. http://bit.ly/3MGOV67. Published March 15, 2023. Accessed April 13, 2023. Schedule of dates. ASHP Match | Schedule. https://bit.ly/3I8MJA7. Published March 15, 2023. Accessed April 13, 2023. 

I chanced upon getting to know Colonel Gautam Guha a few years back in 2020 when he was at his best sharing his learnings and impacting lives. Col Gautam Guha is an Infantry Officer from the Indian Army of the 1990 NDA batch. Like any other military man, Gautam had served in varied operational locations throughout his service including the lofty heights of Siachen Glacier, and also served on deputation with the elite NSG (Black Cats). His health deteriorated after a spinal injury in 2013. He started to put on weight after that and was diagnosed with Diabetes (T2) in Dec 2015 at Military Hospital Trivandrum. As part of the Army's routine medical procedures, he later became a permanent medical category (P3) for Metabolic Syndrome in 2016 with ailments like Hypertension, Dyslipidemia, early onset of Hypothyroidism and Obesity (besides Diabetes T2). In the year 2018, the officer reversed his Diabetes and other ailments with diet, exercise and lifestyle corrections and officially got upgraded in his medical board in 2019. Besides getting rid of all his medications, he also lost 37 kg in this process. For the past two years, after his story was made public by ADGPI ( Additional Directorate General of Public Information), Integrated Headquarters, Ministry of Defence (IHQ of MoD) on its social media platforms like Twitter and Facebook, because of which more people started approaching him, Colonel Gautam Guha embarked upon a journey with a social cause to spread the awareness of ‘Diabetes & Obesity Reversal' and has helped hundreds of people from all walks of life reverse their lifestyle diseases including Hypertension, Dyslipidemia, Hypothyroidism and PCOS besides Diabetes. Colonel Guha is a living example that Diabetes can be reversed and this podcast captures his experience and views in his own words! He is a motivational health speaker and has spoken at numerous forums including platforms like Health Care Product Summit (HCPS) 2020 at Hyderabad in Jan 2020. He has his own YouTube channel and also made health groups on WhatsApp and telegram app where he guides people through their reversal journey and helps them to lead a medicine-free life.

Below is the patient case information: 63-year-old white male. Problem List Bipolar II disorder Insomnia Epilepsy (tonic-clonic seizures) Dyslipidemia/hypertriglyceridemia Hypertension Recent weight gain History of hyponatremia  Diabetes type 2(controlled) Medications Clonazepam 2 mg QHS Risperdal 2 mg twice daily Carbamazepine 200 mg twice daily Divalproex DR 500 mg three times daily Levetiracetam 1000 mg twice daily Losartan 100 mg daily HCTZ 25 mg daily Atorvastatin 40 mg daily Fenofibrate 48 mg daily Metformin ER 500 mg twice daily Vitals: Blood pressure is currently 144/86 mmHg Lipids: LDL-C: 98 Triglycerides: 245 (down from 423 4 months ago) CMP: Na+: 133 K+: 4.1 eGFR: 95 All others WNL as well CBC: Hgb: 10:1 g/dL MCV: 73 Ferritin: 17 A1c: 6.9% Current Appointment The patient has seen multiple neuro and psych providers over the last year.  The R­­isperdal and divalproex were for the bipolar II disorder. The patient is experiencing depression symptoms. His family notes that he has also been uncharacteristically aggressive lately and becomes agitated over minor issues. His family has recently noticed that while talking with him, his face is grimacing, his tongue will randomly protrude from his lips, as well as other facial movements. The clonazepam for insomnia. It helped with insomnia symptoms for a few weeks, but the symptoms are back to pre-treatment baseline. He was taking clonazepam 1 mg 2 hours prior to bed and zopidem 5 mg 30 minutes prior to bedtime. He didn't feel like the zolpidem was working. The clonazepam was increased to 2 mg and the zolpidem was DC'd. He is also complaining of daytime fatigue He was recently hospitalized due to hyponatremia. The carbamazepine and levetiracetam were for seizure control. However, the patient has experienced multiple seizures per month for at least the last 3 months. Needs better blood pressure and triglyceride control Thanks for listening! We want to give a big thanks to our main sponsor Pyrls. Try out their drug information app today. Visit the website below for a free trial: www.pyrls.com/corconsultrx If you want to support the podcast, check out our Patreon account. Subscribers will have access to all previous and new pharmacotherapy lectures as well as downloadable PowerPoint slides for each lecture. You can find our account at the website below:  www.patreon.com/corconsultrx If you have any questions for Cole or me, reach out to us on any of the following: Text - 415-943-6116 Mike - mcorvino@corconsultrx.com Cole - cswanson@corconsultrx.com Instagram and other social media platforms - @corconsultrx This podcast reviews current evidence-based medicine and pharmacy treatment options. This podcast is intended to be used for educational purposes only and is intended for healthcare professionals and students. This podcast is not for patients and not intended as advice or treatment.